Antengene Corp. Secures Licensing Deal with Hansoh Pharmaceutical for Xpovio in China
China-based biopharmaceutical company Antengene Corp., Ltd (HKG: 6996) has announced a significant licensing agreement with...
Novo Nordisk’s H1 2023 Financials Show 30% YOY Growth Driven by GLP-1 Drugs and Obesity Sales
Denmark-based pharmaceutical company Novo Nordisk A/S (NYSE: NVO) has announced its financial results for the...
Pfizer Faces Whistleblower Lawsuit Over Alleged FCPA Violations in China
A former employee of Pfizer Inc., (NYSE: PFE), Frank Han, has filed a civil lawsuit...
Organon Reports Q2 2023 Revenue Growth, Driven by Women’s Health and Biosimilars
US-based Organon (NYSE: OGN) has reported its financial results for the second quarter of 2023,...
Regeneron Pharmaceuticals Acquires Decibel Therapeutics for Hearing Loss Gene Therapies
US-based biopharmaceutical company Regeneron Pharmaceuticals Inc., (NASDAQ: REGN) has announced the acquisition of fellow US...
Denali Therapeutics and Takeda Halt Development of Alzheimer’s Drug Candidate TAK-920/DNL919
US-based biopharmaceutical company Denali Therapeutics Inc., (NASDAQ: DNLI) has announced in its Q2 2023 financial...
Poseida Therapeutics Secures $50 Million Investment from Astellas for Cell and Gene Therapy
US-based cell and gene therapy developer Poseida Therapeutics, Inc. (NASDAQ: PSTX) has announced a significant...
Lee’s Pharmaceutical’s Subsidiary Completes Phase III Study for Myopia Treatment NVK002
China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary, Zhaoke Ophthalmology Ltd (HKG: 6622), has announced...
Eyebright Medical Technology’s Intraocular Lenses Earn Fast-Track Status in China
Beijing-based Eyebright Medical Technology Co., Ltd (SHE: 688050) has announced that its “intraocular lenses with...
Neurophth Biotechnology Secures RMB700 Million in Series C+ Financing for Gene Therapy Development
China-based gene therapy specialist Neurophth Biotechnology Ltd has reportedly secured close to RMB700 million in...
Novartis Reports Positive Phase III Results for Remibrutinib in Chronic Spontaneous Urticaria
Swiss pharmaceutical giant Novartis AG (NYSE: NVS) has announced positive data from the Phase III...
Burning Rock Partners with AstraZeneca to Develop Companion Diagnostics for Cancer Therapies
Guangzhou-based medical device giant Burning Rock (NASDAQ: BNR) has announced a strategic partnership with AstraZeneca...
Audit Reveals Illicit Payments and Inflated Prices in Pharmaceutical Industry
An audit has shed light on the use of third-party business promotion companies as a...
Eli Lilly & Co. Reports 28% YOY Revenue Increase in Q2 2023 Financials
US pharmaceutical giant Eli Lilly & Co., (NYSE: LLY) has released its financial results for...
FibroGen’s Evrenzo Achieves Record Sales in China, Outlook for 2024 Remains Promising
US-based biopharmaceutical company FibroGen Inc., (NASDAQ: FGEN) has released its financial report for the second...
Bayer AG Reports Q2/H1 2023 Financials with Challenges in Crop Science and Pharmaceuticals
Germany-based multinational Bayer AG (ETR: BAYN) has released its financial report for the second quarter...
Novo Nordisk’s Wegovy Demonstrates 20% Reduction in Cardiovascular Events in SELECT Trial
Denmark-based pharmaceutical giant Novo Nordisk A/S (NYSE: NVO) has released topline data supporting the use...
Shanghai Health Commission Issues Regulations to Curb Unhealthy Pharmaceutical Practices
In alignment with the No. 75 Document by the National Health Commission, the Shanghai...
CanSino Biotechnology Partners with AstraZeneca for mRNA Vaccine Development and Manufacturing
China-based vaccines specialist CanSino Biologics Inc., (HKG: 6185) has announced a product supply cooperation framework...
Lynk Pharmaceuticals’ LNK01001 Shows Positive Results in Atopic Dermatitis Phase II Study
China-based Lynk Pharmaceuticals Co., Ltd has announced that its Phase II clinical study for LNK01001...